Information om förpackningar av Metoject® (metotrexat)

Till följd av att allt fler användare av parenteralt metotrexat föredrar att använda Metojectpen® (förfylld injektionspenna) istället för Metoject® (förfylld spruta), anpassar Medac sig nu genom att minska ner antalet förpackningar av sprutorna, framför allt av de doser som börjar bli små i volym.

De förpackningar/doser som nu successivt tas ur sortimentet är;

Fortsatt kommer vi självklart att ha fullt sortiment av Metojectpen® (7,5 mg-30 mg).




Har du frågor eller funderingar, vänligen kontakta Peter Larsson eller Samira Nyman.

 

 

 

 

Press release – First marketing authorisation worldwide for methotrexate in moderate psoriasis

Medac’s marketing authorisation extension gives many patients with psoriasis access to guidelines-based MTX therapy for the first time.


Click here to view full Press release

Press release – Alacare®

Innovative therapeutic for the treatment of mild actinic keratoses –
first self-adhesive patch for PDT

  • The skin lesion actinic keratosis is associated with an estimated prevalence of up to 60 % in certain populations and bears a high disease burden being considered as precancerous
  • The treatment option with the ALA-PDT patch has not only been proven to be very easy to use and time-saving, but also to be more effective compared to cryotherapy regarding clearance rates, recurrences and pigmentation disorders
  • The first medical patch Alacare® has been launched first in Sweden and will be available in the United Kingdom, Denmark, Finland, Norway and Poland at the beginning of next year. Further countries will follow

Click here to view full Press release

Click here to view FactSheet